CervoMed

CRVO

Market cap $77M

Overview Fund Activity

8.85 USD

-0.35

3.8%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

8.77

-0.08

0.9%

1 day

-3.8%

5 days

-15.79%

1 month

-5.85%

3 months

16.14%

6 months

43.44%

Year to date

296.86%

1 year

-47.88%

5 years

-87.89%

10 years

-99.81%

About: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 15

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1.27% less ownership

Funds ownership: 26.24% [Q1] → 24.97% (-1.27%) [Q2]

9% less funds holding

Funds holding: 45 [Q1] → 41 (-4) [Q2]

29% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 14

35% less capital invested

Capital invested by funds: $20.9M [Q1] → $13.7M (-$7.24M) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 18

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

24% upside

Avg. target

$20

126% upside

High target

$31

250% upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	$11	Neutral Reiterated	8 Sep 2025
D. Boral Capital Jason Kolbert	$31	Buy Maintained	18 Aug 2025
Roth Capital Boobalan Pachaiyappan	$16	Buy Reiterated	12 Aug 2025
Chardan Capital Daniil Gataulin	$15	Buy Maintained	11 Aug 2025
Canaccord Genuity Sumant Kulkarni	$27	Buy Maintained	29 Jul 2025

See Analyst Rankings

Financial journalist opinion

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:

CervoMed to Participate in Upcoming Investor Conferences

CervoMed's Dementia Data Show Slowed Disease Progression

CervoMed Inc. CRVO on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with Dementia with Lewy Bodies (DLB).

CervoMed's Dementia Data Show Slowed Disease Progression

Zacks Investment Research

CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?

CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening)

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer's Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Zacks Investment Research

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

See News Rankings

Charts implemented using Lightweight Charts™